The Telmisartan Market is projected to reach USD 4.68 billion by 2033, up from USD 3.54 billion in 2023, growing at a compound annual growth rate (CAGR) of 3.47% over the forecast period. This market pertains to the pharmaceutical sector's focus on Telmisartan, a drug used primarily for managing hypertension (high blood pressure). Telmisartan, classified as an angiotensin II receptor blocker (ARB), functions by relaxing blood vessels to lower blood pressure and enhance blood flow.
The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.
Segments covered
By Indication (Hypertension and Cardiovascular Risk Reduction)
By Sales Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies)
Key players
Abbott Laboratories
Aurobindo Pharma
Boehringer Ingelheim International GmbH
Cipla Inc
Glaxosmithkline Plc
Mylan N.V.
Sanofi
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd
Zydus Cadila
- Chapter 1. Executive Summary
- Chapter 2. Scope Of The Study
- 2.1. Market Definition
- 2.2. Scope Of The Study
- 2.2.1. Objectives of Report
- 2.2.2. Limitations
- 2.3. Market Structure
- Chapter 3. Evolve BI Methodology
- Chapter 4. Market Insights and Trends
- 4.1. Supply/ Value Chain Analysis
- 4.1.1. Raw End Users Providers
- 4.1.2. Manufacturing Process
- 4.1.3. Distributors/Retailers
- 4.1.4. End-Use Industry
- 4.2. Porter’s Five Forces Analysis
- 4.2.1. Threat Of New Entrants
- 4.2.2. Bargaining Power Of Buyers
- 4.2.3. Bargaining Power Of Suppliers
- 4.2.4. Threat Of Substitutes
- 4.2.5. Industry Rivalry
- 4.3. Impact Of COVID-19 on the Telmisartan Market
- 4.3.1. Impact on Market Size
- 4.3.2. End-Use Industry Trend, Preferences, and Budget Impact
- 4.3.3. Regulatory Framework/Government Policies
- 4.3.4. Key Players' Strategy to Tackle Negative Impact
- 4.3.5. Opportunity Window
- 4.4. Technology Overview
- 12.28. Macro factor
- 4.6. Micro Factor
- 4.7. Demand Supply Gap Analysis of the Telmisartan Market
- 4.8. Import Analysis of the Telmisartan Market
- 4.9. Export Analysis of the Telmisartan Market
- Chapter 5. Market Dynamics
- 5.1. Introduction
- 5.2. DROC Analysis
- 5.2.1. Drivers
- 5.2.2. Restraints
- 5.2.3. Opportunities
- 5.2.4. Challenges
- 5.3. Patent Analysis
- 5.4. Industry Roadmap
- 5.5. Parent/Peer Market Analysis
- Chapter 6. Global Telmisartan Market, By Indication
- 6.1. Introduction
- 6.2. Hypertension
- 6.3. Cardiovascular Risk Reduction
- Chapter 7. Global Telmisartan Market, By Sales Channel
- 7.1. Introduction
- 7.2. Hospital Pharmacies
- 7.3. Drug Stores and Retail Pharmacies
- 7.4 Online Pharmacies
- Chapter 8. Global Telmisartan Market, By Region
- 8.1. Introduction
- 8.2. North America
- 8.2.1. Introduction
- 8.2.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.3. Market Size and Forecast, By Country, 2023-2033
- 8.2.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.2.5. Market Size and Forecast, By End User, 2023-2033
- 8.2.6. US
- 8.2.6.1. Introduction
- 8.2.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.6.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.2.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.2.7. Canada
- 8.2.7.1. Introduction
- 8.2.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.2.7.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.2.7.5. Market Size and Forecast, By End User, 2023-2033
- 8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.3. Market Size and Forecast, By Country, 2023-2033
- 8.3.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.5. Market Size and Forecast, By End User, 2023-2033
- 8.3.6. Germany
- 8.3.6.1. Introduction
- 8.3.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.6.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.7. France
- 8.3.7.1. Introduction
- 8.3.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.7.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.7.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.8. UK
- 8.3.8.1. Introduction
- 8.3.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.8.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.8.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.9. Italy
- 8.3.9.1. Introduction
- 8.3.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.9.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.9.4. Market Size and Forecast, By End User, 2023-2033
- 8.3.11. Rest Of Europe
- 8.3.11.1. Introduction
- 8.3.11.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.3.11.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.3.11.4. Market Size and Forecast, By End User, 2023-2033
- 8.4. Asia-Pacific
- 8.4.1. Introduction
- 8.4.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.3. Market Size and Forecast, By Country, 2023-2033
- 8.4.4. Market Size and Forecast, By Product Type, 2023-2033
- 8.12.28. Market Size and Forecast, By End User, 2023-2033
- 8.4.6. China
- 8.4.6.1. Introduction
- 8.4.6.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.6.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.6.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.7. India
- 8.4.7.1. Introduction
- 8.4.7.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.7.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.7.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.8. Japan
- 8.4.8.1. Introduction
- 8.4.8.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.8.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.8.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.9. South Korea
- 8.4.9.1. Introduction
- 8.4.9.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.9.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.9.4. Market Size and Forecast, By End User, 2023-2033
- 8.4.10. Rest Of Asia-Pacific
- 8.4.10.1. Introduction
- 8.4.10.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.4.10.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.4.10.4. Market Size and Forecast, By End User, 2023-2033
- 8.5. Rest Of The World (RoW)
- 8.5.1. Introduction
- 8.5.2. Driving Factors, Opportunity Analyzed, and Key Trends
- 8.5.3. Market Size and Forecast, By Product Type, 2023-2033
- 8.5.4. Market Size and Forecast, By End User, 2023-2033
- Chapter 9. Company Landscape
- 9.1. Introduction
- 9.2. Vendor Share Analysis
- 9.3. Key Development Analysis
- 9.4. Competitor Dashboard
- Chapter 10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Business Overview
- 10.1.2. Government & Defense Analysis
- 10.1.2.1. Government & Defense – Existing/Funding
- 10.1.3. Product Portfolio
- 10.1.4. Recent Development and Strategies Adopted
- 10.1.5. SWOT Analysis
- 10.2. Aurobindo Pharma
- 10.2.1. Business Overview
- 10.2.2. Government & Defense Analysis
- 10.2.2.1. Government & Defense – Existing/Funding
- 10.2.3. Product Portfolio
- 10.2.4. Recent Development and Strategies Adopted
- 10.2.5. SWOT Analysis
- 10.3. Boehringer Ingelheim International GmbH
- 10.3.1. Business Overview
- 10.3.2. Government & Defense Analysis
- 10.3.2.1. Government & Defense – Existing/Funding
- 10.3.3. Product Portfolio
- 10.3.4. Recent Development and Strategies Adopted
- 10.3.5. SWOT Analysis
- 10.4. Cipla Inc
- 10.4.1. Business Overview
- 10.4.2. Government & Defense Analysis
- 10.4.2.1. Government & Defense – Existing/Funding
- 10.4.3. Product Portfolio
- 10.4.4. Recent Development and Strategies Adopted
- 10.12.28. SWOT Analysis
- 10.5. Glaxosmithkline Plc
- 10.5.1. Business Overview
- 10.5.2. Government & Defense Analysis
- 10.5.2.1. Government & Defense – Existing/Funding
- 10.5.3. Product Portfolio
- 10.5.4. Recent Development and Strategies Adopted
- 10.5.5. SWOT Analysis
- 10.6. Mylan N.V.
- 10.6.1. Business Overview
- 10.6.2. Government & Defense Analysis
- 10.6.2.1. Government & Defense – Existing/Funding
- 10.6.3. Product Portfolio
- 10.6.4. Recent Development and Strategies Adopted
- 10.6.5. SWOT Analysis
- 10.7. Sanofi
- 10.7.1. Business Overview
- 10.7.2. Government & Defense Analysis
- 10.7.2.1. Government & Defense – Existing/Funding
- 10.7.3. Product Portfolio
- 10.7.4. Recent Development and Strategies Adopted
- 10.7.5. SWOT Analysis
- 10.8 Sun Pharmaceutical Industries Limited
- 10.8.1. Business Overview
- 10.8.2. Government & Defense Analysis
- 10.8.2.1. Government & Defense – Existing/Funding
- 10.8.3. Product Portfolio
- 10.8.4. Recent Development and Strategies Adopted
- 10.8.5. SWOT Analysis
- 10.9 Teva Pharmaceutical Industries Ltd
- 10.9.1. Business Overview
- 10.9.2. Government & Defense Analysis
- 10.9.2.1. Government & Defense – Existing/Funding
- 10.9.3. Product Portfolio
- 10.9.4. Recent Development and Strategies Adopted
- 10.9.5. SWOT Analysis
- 10.10. Zydus Cadila
- 10.10.1. Business Overview
- 10.10.2. Government & Defense Analysis
- 10.10.2.1. Government & Defense – Existing/Funding
- 10.10.3. Product Portfolio
- 10.10.4. Recent Development and Strategies Adopted
- 10.10.5. SWOT Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook